EGM of the company scheduled to be held on November 01, 2025 at 11.30 am through VC.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals has called an Extra-Ordinary General Meeting on November 01, 2025 (11:30 AM) via video conferencing to seek shareholder approval for issuing 46,43,000 Convertible Equity Warrants to promoters/promoter group at Rs. 34 per warrant (including Rs. 33 premium), aggregating to Rs. 15.79 crore. Allottees include Anar Jayeshbhai Patel, Dakshesh Shah, Anar Project Pvt Ltd, Parshva Texchem India Pvt Ltd, and Navkar Surgical Gujarat Ltd — all promoters or promoter group entities. Warrants carry an 18-month tenure, with 25% payable upfront and 75% on exercise. Proceeds are earmarked for working capital and bank guarantee margin (Rs. 9 cr), capital expenditure in subsidiaries (Rs. 6.70 cr), and general corporate purposes (Rs. 0.0862 cr). Promoter shareholding will rise marginally from 50.96% to 51.47%, with no change in control.
This is a promoter-backed capital raise of roughly Rs. 15.79 crore, which is positive as it signals promoter confidence and brings in funds for working capital and subsidiary expansion. However, since warrants are priced at Rs. 34 (a premium to current market) and will lead to dilution upon conversion, existing non-promoter shareholders may see their stake diluted slightly once warrants are exercised over the next 18 months.